PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 12, 2026Advanced Biology5 citationsOpen Access

Personalized Models of Biological Barriers and Their Diseases: Recent Progress with Organs‐On‐Chips

View Full Paper
FBFranziska BuckJBJeroen M. BugterGYGizem Yorukoglu

Key Points

  • The central aim is to explore how organs-on-chips can advance the understanding and modeling of diseases related to barrier tissues.
  • Survey of architectural diversity and functions of human barrier systems
  • Review of organs-on-chips platforms using patient-derived and iPSC-derived cells
  • Assessment of the progress in disease modeling and drug testing
  • Organs-on-chips effectively mimic barrier microenvironments and patient-specific characteristics
  • Existing technologies show potential for developing disease models and personalized drug testing
  • Continued improvement in iPSC protocols and OoC design is crucial for future advancements

Abstract

ABSTRACT Barrier tissues—epithelial and endothelial interfaces that compartmentalize the human body—govern molecular exchange, immune surveillance, and organ homeostasis. Their dysfunction is central to disorders ranging from dermatitis to neurodegeneration. Conventional static cultures fail to capture the relevant microenvironment and typically rely on cell lines that overlook patient‐specific genetics. Organs‐on‐chips (OoCs), by contrast, can recapitulate barrier‐specific flow, biomechanics, chemical gradients, and a multicellular architecture. Additionally, incorporating primary or induced pluripotent stem cell (iPSC)‐derived cells into OoCs can open new avenues for precision medicine. This review surveys the architectural diversity and physiological functions of human barrier systems and explores how OoC platforms—especially those using patient‐derived cells—are advancing barrier disease modeling. It reveals similar core features but also unique barrier characteristics requiring specific adaptations, resulting in varied progress across systems, and continued refinement of iPSC differentiation protocols and OoC engineering is needed overall. Nevertheless, existing biological and technological advances already offer substantial, untapped opportunities to create physiologically relevant, patient‐specific disease models and drug‐testing platforms, bridging the gap between fundamental biology and translational medicine.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Buck et al. (2026) studied this question.

synapsesocial.com/papers/698d6eca5be6419ac0d54905https://doi.org/10.1002/adbi.202500536
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bioengineered Humanoid-on-Chip Platforms: Tools for Evaluating the Effects of Environmental Exposure on Human Physiological Barriers2025 · 1 citations
  2. 2Advancing Organ-on-a-Chip Technologies: A Review on the Multi-Organ Approach for Precision Disease Modeling and Drug Screening2026
  3. 3In vitro immunity: an overview of immunocompetent organ-on-chip models2024 · 53 citations
  4. 4Advancing Blood–Brain Barrier-on-a-Chip Models Through Numerical Simulations2024 · 18 citations
  5. 5Exploring Organ-on-Chip Systems as Functional Bioassays for Drug Screening: Principles and Models2025